Article Sidebar

PDF
Date Published: 12/06/2021
Abstract Views: 393
Views PDF: 241
DOI: https://doi.org/10.51298/vmj.v500i2.388
Issue
Vol. 500 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Nhân, N. ., Thanh Hải, N. ., Hồng Chiến, L. ., Văn Đoan, N. ., & Thị Hậu, V. . (2021). INITIAL VALUE OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING BASED ON PI-RADSv2.1 TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER. Vietnam Medical Journal, 500(2). https://doi.org/10.51298/vmj.v500i2.388

INITIAL VALUE OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING BASED ON PI-RADSv2.1 TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER

Nguyễn Thị Nhân, Nguyễn Thanh Hải, Lê Hồng Chiến, Ngô Văn Đoan, Vũ Thị Hậu

Main Article Content

Abstract

Purpose: This study analyzes the initial value of multiparametric magnetic resonance imaging (mpMRI) according to the PI-RADSv2.1 guideline to detect clinically significant prostate cancer. Materials and Methods: The prospective study included 30 patients with 38  prostatic lesions at the Vinmec Times City International Hospital from July 2018 to January 2021. We classify prostatic lesions detected on mpMRI according to PI-RADSv2.1 guidelines. The suspicious lesions were biopsied by transrectal ultrasound (TRUS) guided. The correlation between the prostate lesion on mpMRI and the histopathological result of transrectal ultrasound (TRUS) guided biopsy specimens was properly analyzed. Results: Clinically significant prostate cancer ratio based on PI-RADS categories £2, 3, 4, 5  was 0%, 12.5%; 58.3%; 85.7%, respectively. PI-RADS 3 category only saw in prostate cancer Gleason groups 1 and 2; PI-RADS 4, 5 categories was showed in prostate cancer Gleason groups ³2. Conclusion: Multiparametric magnetic resonance imaging has a considerable value in detecting clinically significant prostate cancer with substantial correlation between PI-RADS 4, 5 categories and Gleason grading system in prostate cancer.

Article Details

Keywords

Prostate cancer, PI-RADSv2.1, Gleason grading system

References

1. Sung H., Ferlay J., Siegel R.L., et al. (2020). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2. Peter R., J. Kellogg P., Geoffrey B., et al. (2021). Prostate cancer early detection Version 1.2021. National Comprehensive Cancer Network. 68, 7.
3. European society of Urogenital Radiology. (2019). Revisions in PI-RADS v2.1. American College of Radiology. 29.
4. Tamada T. (2019). Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Eur J Radiol, 6.
5. Mythreyi C., Lauren H., Dipleen K., et al. (2019). Prostate Imaging - Reporting and Data System 2019 Version 2.1. ACR-ESUR-AdMeTech 2019. 76.
6. Walker S.M., Mehralivand S., Harmon S.A., et al. (2020). Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. Am J Roentgenol, 215(5), 1098–1103.
7. Patel P., Wang S., and Siddiqui M.M. (2019). The Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in the Detection, Evaluation, and Surveillance of Clinically Significant Prostate Cancer (csPCa). Curr Urol Rep, 9.
8. Katz A., Liu C., and Kosinski K.E. (2016). Histopathologic correlation of PI-RADS V.2 lesions on 3T multiparametric prostate MRI. J Clin Oncol, 34(2), 10–10.
9. Alqahtani S., Wei C., Zhang Y., et al. (2020). Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system. Sci Rep, 10(1), 7722.